Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sums up how we feel about you
The question is.... If DARPA green lights the product what would be next steps? Does the 5 year testing serve as a replacement for FDA trial?
How long until they can use for Sepsis treatment ?
23000 cases world wide is a speck compared to sepsis alone
Sepsis is potentially a virus that the Hemopurifier can cure on its own. Depending on country about .2 to 3 people per thousand get sepsis. Tha means that you are 250000 times more likely to get Sepsis this year in the US than Ebola and that's counting those who caught it outside the U.S. and brought it in
To put that in perspective If Ebola was current AEMD share of .32 cents
SEPSIS. Is $80,000 per share.
There are 1 million cases in the US each year and climbing with approx 250,000 related deaths in the US
That's approx 7-10 million cases worldwide each year and 1/4 to 1/3 of those people die
No cure.
Of course the DARPA group sponsored by UNCLE SAM thought enough of AEMD to spend millions and 5 years of testing to help cure the masses. This is just ONE of the real game changers for AEMD
EBOLA is serious but in scale it's town rec T-Ball in compared to the Major league ALL STAR game.
EBOLA gets pumpers excited for short money.
AEMD gets me excited for being a life changer and this story could repeat for HIV. Hep C. , Dengue.. Cancer. Etc
Why no orders? No demand
You have 350,000,000 people approx in the United States and 4/5 Ebola cases in 9 months mostly from patients who have been shipped in to the U.S.
There is no demand. Germany has had 3 or 4 cases also. England a couple
No demand. Also. We aren't a cure for this disease. We assist in fighting Ebola and reducing viral load
The company will move as all products do once proven
If you were drawn to AEMD expecting huge revenue from Ebola then you will be seeking those questions for a long time. At its current world exposure Ebola barely scratches the surface in numbers in regards to issues such as Hep C. HIV, Cancer, Dengue and Sepsis to name a few biggies. These are world issues with Annual patients in the millions to 10's of millions
Ebola provides exposure
These others move mountains
Patience
The reverse split for CTSO was 25-1. You will need to get to 75.00 a share to break even if you paid 3.00
Patent infringement should be way down on the list of concerns
Maybe CTSO should worry about patent infringement on all of AEMD's many patents by your logic
That was my order. I had a GTC for some shares and dropped it
Not manipulation
They are not selling product yet. They have been in testing and development for a decade The DARPA tests and FDA trials will be complete by end of 2015
MGH is aware of the filter. They, along with Harvard and Oxford, have done in vitro cancer studies regarding exosome research
My thoughts are that I agree with you
There is a ton of hype right now based on Ebola but ebola is not AEMD target audience. Currently is serves to market AEMD to the public That's great
Last spring and this summer they added 50 million shares and have added 30% a year to float for years now. The recent add took us from around .23-.24 to .11 in months. They have to issue shares because sales from cleared FDA approved trials are likely 2-3 years away
That is a lot of stress and dilution.
If you believe in this product the payoff should really begin in 3-5 years but I suspect this could snap back soon to reality
Be prepared and hang on. Breaking .50 Would be a likely drop to .42 then breaking that its a drop to .327
TIME is announcing an Invention of the year that was developed almost a decade ago. Amusing
Love Aemd. But I suspect many dont know that EBOLA is not its answer to success.
We are not a cure. We are a novel idea that is a fantastic adjunct solution
Best wishes
DOC
Shaw had a conversion not a buy
That's a Huge if and highly unlikely not because the filter isnt effective. The HP Filter is effective but 98% is near perfect and there are too many variables in each patient. Age, health, progression of disease etc etc
Thet just don't know enough about how to stop it with live patients since invitro was the only prior testing
I am happy winning small battles for now
Ebola buys AEMD exposure worth millions
Best wishes
DOC
Yes I am
Over 7 figure in shares
I can wait
We don't know that at all MEZTIC
It's been one patient. JJ will tell you himself the filter is Not a cure.
What we know is that the same patient was given two other drugs and they can establish that the filter withdrew 399k of viral load cells. What we don't know is if those cells were the ones remaining from what the meds killed off? Was one filter treatment ideal or should there have been several? What if you removed the dosage of one of the drugs given? Increased it? What if we was brought in a day or more later like the doc in Nebraska? Had the meds killed millions of cells and we did the rest? Was he on he way back anyway? What drug combo really helped? Would it be better to give a patient the Hp earlier in the treatment or is later better? Is there a better drug to pair with the filter because the filter is not the cure.... The filter doesn't remove a tumor from an intestine it only reduces the viral load the tumor secretes into the blood stream. What if next time the patient or patients are not treated by a team of over thirty doctors and nurses around the clock? What if the avg cost of medicine and other treatment makes dialysis machines take a back burner?
Point is... We have one patient who lived.... What cured him for sure.... No one knows
Our involvement is promising
Many more patients are needed and as excited as I was to hear today's news of Emergency FDA Approval use. (Btw. FDANEWS.COM YOU WERE WRONG). Hopefully Ebola is stopped. I don't expect the US to get a flood of patients who may or may not use the HP. Zmap has proven more effective.
But even if we do AEMD gains exposure but likely loses money sending staff to places to monitor the first uses of this filter on patients. EBOLA with even a 1000 patients would not be the answer for AEMD.
THE FUTURE is with the other treatments I mentioned. As bad as they can be the world does not fear them as we do Ebola. But in years from now when we are treating potentially endless patients for numerous reasons....then you will know this companies potential.
Best Wishes
DOC
Aemd State of Affairs
The 8k is a lease renewal which means nothing since they were in he same building and space there were before
the past three days look much like the week of Oct 14 where the stocked gapped up from .15 to a high of .30 and retraced to .20 and even below by Monday. It churned at that low 20 range for a month. After days of large double digit gains by pumped and hucksters trying to inflate price they will get squirrelly of news does not continue to flow and we dip to .35 and below.
I don't care but the volatility may get hot in the next 2-5 days IMO. The float is large and it's not exactly a short term play. Realistically this is years from achiving it's goals but thats ok. I bought this stock long ago waiting for its development to play out and expect that to happen or start in 2016. Post DARPA, post HCV STUDY, 2017 with Dengue and Cancer, maybe beyond with CTE
Ebola clearly spotlights the companies ability but with present cases it won't pay the bill. The future should
If you are long it likely doesn't matter because it's time will come. If you don't have 2 plus years......well
Best Wishes
Belt in ....nothing is straight up..ESPECIALLY after 300% gain. (thank you aemd)
DOC
8k is a very exciting
Lease Contract to renew the lease in their present building
.434 & .50 are not resistance
Your making things up now
.44 was high of day but not resistance. .478 is the high thus the resistance at this point
Let me help you..."" YEAH!!!!! LOUD NOISES!!! MOON SHOT!!"
There you go
Your welcome . Continue
Unlikely reason to go to Geneva.
5400 miles for that trip compared to 211 to Miami. Why take that time and risk?
Or for that matter smarter to go to Frankfurt
Actually price before gap was .327.
There is another size able gap in the 20's.
It will all be fine
We have two manufacturer agreements that I know of with one in Europe and another with a company in the south (Kentucky). It is a plant based lectin made from tobacco plants. I do Forster a shortage as growing aggie can be ramped up in short order.
The FDA only has approved the IDE study which is starting now for HCV and AEMD is expected to submit an IDE study proposal for Cancer in Q1.
If you want some real excitement consider this....Device patents are for TWENTY YEARS
As compared to :
Orphan drug 7 years
New Chemicsl: 5 years
Exclusivity: 3 years
The future is so bright you better wear two pairs of welders glasses.
As for gross margin... No idea. The large device supposedly sells for approx 1200.00 each
Treatments for HCV and HIV require multiple treatments
The annual patient base for the major known uses such as Sepsis, HCV, HIV , Cancer , Dengue and EBOLA is in the 100's of millions
He suspect he means right now. He is undergoing chemo
Ebola fight far from over
(I suspect it will only be a matter of time until the HP is brought into Africa to help. Dr Michael Mawanda is a WHO affiliate. The WHO is well aware of the use and I believe they would be looking to set up further use of the HP to further test its results (if not being done slready) nThe reported numbers for the death toll have stayed in the same 200 person range for weeks now. Two weeks ago the death toll report actually declined but the case rate has contined up. With a 70% death rate I expect, due to economic implications, some powers that be are influencing numbers until they feel they can get Ebola under control. Heaven help us if it gets to India, China or for a real US immigration issue, Central America Aethlon will be in the center of this fight shortly)
http://rt.com/news/201567-ebola-sierra-leone-toll-underreported/
Ebola’s toll on Sierra Leone is much greater than previously thought, with entire villages killed off by the virus. This means up to 20,000 people could have succumbed to the disease by now, a senior coordinator for Doctors Without Borders (MSF) believes.
READ MORE: Canada imposes visa ban on Ebola-hit African countries
According to Rony Zachariah, coordinator of operational research for MSF, the Ebola impact on Sierra Leone is in fact “under-reported,” AFP quotes.
“The situation is catastrophic. There are several villages and communities that have been basically wiped out. In one of the villages I went to, there were 40 inhabitants and 39 died,” Zachariah told the agency. “Whole communities have disappeared but many of them are not in the statistics. The situation on the ground is actually much worse.”
The latest figures from the World Health Organization (WHO) put the total number of dead at 4,951 out of 13,567 recorded cases.
But the real total could be up to 20,000 people dead, Zachariah argues. “The WHO says there is a correction factor of 2.5, so maybe it is 2.5 times higher and maybe that is not far from the truth. It could be 10,000, 15,000 or 20,000.”
Zachariah also highlighted the shortage of healthcare workers in the country.
READ MORE: Ebola hospital ship docks in Sierra Leone in UK aid effort
“You have one nurse for 10,000 people and then you lose 10, 11, 12 nurses. How is the health system going to work?” he said.
Even at this point, the pace of dealing with Ebola is slow, he added. “We might get a vaccine and a treatment...but even now we need to go much faster because the clock is ticking...We want action now.”
Meanwhile, the latest cases of Ebola in Spain and the US have sparked fears of an even bigger outbreak, prompting Canada to step up its border security so as to limit the risk of infection spreading into the country.
The federal government announced on Friday it is suspending the processing of visa applications for residents and nationals who have been in Guinea, Liberia, and Sierra Leone in the last three months. The same goes for permanent residence applications.
READ MORE: ISIS eyes using Ebola as bio weapon – Spain
The Spanish government has expressed grave concern over the threat of terrorists using Ebola as a biological weapon against the West.
Spain’s state secretary for security, Francisco Martinez, addressed the parliament, discussing the possibility of extremists connected to the Islamic State (IS, previously ISIS) using Ebola as a weapon against the West.
There are “many examples” of online terrorist chat logs discussing the use of biological warfare against the West, Spain’s RTVE public broadcasting corporation reported.
That report is wrong. Approved for compassionate use Oct 29th 2014
Just because its written somewhere doesn't make it true
We can assume it won't be long but the FDA doesn't move quickly (or as quick as we wish) nor do they have anything to do with approval of device and drug uses outside of the US (see Germany)
This is why AEMD went to India to test the HP and whY other drugs seek uses outside the US first because in many cases the process is easier.
They can then use trial results in those countries (as Aemd did). To help support IDE approval
I would love nothing more than for all of this to hapPen tomorrow but It doesn't move that fast
This HCV trial was suppose to start almost a year ago, By now the IDE submission for a cancer trial should have been submitted but it is delayed until at least q1 2015, the Dengue trial won't start till earliest end of 2015
Lots going on and AEMD /ESI have few employees and many searing hot irons in the fire
Ebola has been a Bat Signal to get lots of people's attention but we are still virtually unknown. Ask 10 people what Aethlon does and I bet you will go Oh'Fer on correct answers. When some people know then a handful of us here will be set for life.
Best wishes
DOC
JJ at SeeThru Equity on Nov12th slide26
3rd line down
"EBOLA EMERGENCY USE CLEARENCE FROM FDA....PENDING"
Believe me this would be big news if approved. Not yet though. FDANews is wrong
It's ok ... You're new 2030Capital. You and. casual have your hearts in the right place
Best wishes
DOC
That article is wrong. See Aethlon website for news. You won't need to check much since compassionate use( I assume this is where the writer made an error) was approved Oct29th,2014
So I don't recall emergency use getting cleared without a major news release.
I assume all the boards would be lighting up with the news if true
Aethlon Medical Discloses Ebola Treatment Pathways in the United States
Aethlon Medical, Inc.
Oct 29, 2014 7:15 AM
(the below was approved oct 29th of this year. The further approval, if truly approved would have made bigger headlines. The tweet today was not referencing Ebola. I wish it was true but I don't see any supporting data besides a misrepresented and older fdanews article that appears wrong...Doc)
????
SAN DIEGO, Oct. 29, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, disclosed today that it will provide Hemopurifier® therapy under FDA compassionate use access provisions to support potential requests by qualified physicians and institutes that may seek to treat ebola virus infection in the United States.
.
The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans. According to the World Health Organization (WHO), nearly 5,000 deaths have been attributed to the current ebola virus epidemic.
Based on guidance from FDA, the treatment of ebola virus infection provides for a unique circumstance where a physician or health care provider may wish to pursue the compassionate use of Hemopurifier® therapy based on the serious nature of the disease and absence of alternative therapies. Compassionate use provisions are typically approved by FDA on an individual patient basis, but may be expanded to include a small group.
Aethlon also disclosed that it plans to submit its first ebola treatment data to the FDA as a means to support the goal of further expanding treatment access through emergency use regulatory pathways.
On October 14th, 2014, the Company announced that Hemopurifier® therapy had been administered to an ebola-infected patient at Frankfurt University Hospital in Germany. The treatment was permitted through special approval from The Federal Institute for Drugs and Medical Devices (Bundesinstitut fur Arzneimittel und Medizinprodukte, BfArM), an independent federal higher authority within the portfolio of the Federal Ministry of Health of Germany.
"The administration of Hemopurifier® therapy in Germany has reinforced the need to clarify defined regulatory pathways that might allow us to treat ebola infection in the United States," stated Aethlon founder and CEO, Jim Joyce. "As it relates to the patient treated in Germany, we respect patient confidentiality and will report on his response to therapy after Frankfurt University Hospital officials provide an update on his condition."
In the care of ebola-infected individuals, the Hemopurifier® targets two unmet medical needs: the rapid elimination of circulating viruses to inhibit continued progeny virus replication and the direct targeting of shed glycoproteins that overwhelm the host immune response. The device can be deployed for use within the global infrastructure of dialysis and CRRT machines already located in hospitals and clinics.
Aethlon is also preparing to initiate U.S. clinical studies of Hemopurifier® therapy based on the FDA's approval of an Investigational Device Exemption (IDE) that was previously submitted by the Company. The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).
To date, Hemopurifier® therapy has been successfully administered in approximately one hundred treatment experiences in health compromised HIV and HCV infected individuals. These studies were conducted at the Apollo Hospital, Fortis Hospital, Sigma New Life Hospital, and the Medanta Medicity Institute, all located in India. In vitro validation studies that demonstrated the ability of the Hemopurifier to capture Zaire and other strains of ebola virus were conducted by researchers at the United States Army Medical Research Institute for Infectious Diseases (USAMRIID) and the United States Centers for Disease Control and Prevention (CDC).
About Aethlon Medical, Inc.
Aethlon Medical creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. For more information, please visit http://www.aethlonmedical.com/ and connect with the Company on Twitter, LinkedIn, Facebook and Google+.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
(Office) 858.459.7800 x301
(Cell) 619-368-2000
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Logo - http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b
2 different FDA matters on the table
One is the FDA Approved study hat is about to commence on HCv which will lend support to other uses
The second, no approved, is for Emergency use for Ebola. Compassionate use approved but very limited scope
Did you just call me a hater 2030Capital? Lol
Just like true facts. This doesn't need fake hype to succeed
athelon did not tweet that
@Aethlon_Medical: $AEMD will soon begin the 1st US clinical #Hemopurifier studies following the FDA's approval of an IDE submitted http://t.co/Cu8FGYydMn
This has to do with HCV study in Texas not emergency use
Lyme Disease and Epstein Barr
Are both envelope gLycoprotein viruses. In theory both could be treated in part by the HP
At this pace and rate we could see .50 by 2:30 and targeting .53-.55 by 4pm
All nurses.com web posting
Nice when medical professionals start to learn about AEMD
http://allnurses.com/dialysis-renal-urology/hemopurifier-have-you-959717.html
HP world use numbers
Sepsis.
20-30 million cases a year. Current 5 year trial being conducted for US Govt thru DARPA for military and public use. Trail continues as objectives met over past three years
http://www.osacc.org/images/2014_WSD_Declaration_English.pdf
HCV
130-150 million world cases. 350,000-500,000 die each year. FDA approved starting now in Texas with Davita Clinic.
http://www.who.int/mediacentre/factsheets/fs164/en/
HIV
35 million people living with HIV. Clinical Tests for HCV and HIV Completed in India with long term results being publish this month. Approx 100 clinical subjects
http://www.who.int/gho/hiv/en/
Dengue
Clinical trial to start in India in Fall of 2015
Global burden of dengue
The incidence of dengue has grown dramatically around the world in recent decades. Over 2.5 billion people – over 40% of the world's population – are now at risk from dengue. WHO currently estimates there may be 50–100 million dengue infections worldwide every year.
http://www.who.int/mediacentre/factsheets/fs117/en/
Cancer
Current work and focus of ESI. FDA clinical trial submission expected on early 2015
Recent studies done with joint collaboration with Harvard, Oxford , and Mass General
Showed promise with article published in April 2014. This could be ground breaking for combating cancer
CTE
Concussion study currently under way at BU with NFL concussions as main focus
Study to be released in early 2015
Point is....there are just a few uses. ( not all listed here). The future is grand for AEMD
Sepsis brings that to 7.5 million in US
Killing 28-50%
http://www.nigms.nih.gov/Education/Pages/factsheet_sepsis.aspx
In 2008, $14.6 billion were spent on hospitalizations for sepsis in the US. Between 1997 and 2008, total costs for treating patients hospitalized for sepsis increased by an average of 11.9% each year, adjusted for inflation. The costs related to long-term damage resulting from sepsis are unknown. In Germany, the cost of a typical episode of sepsis has more than doubled over the last decade, from approximately 25,000 to 55,000 euros. And the human cost of sepsis is incalculable.
http://www.world-sepsis-day.org/?MET=SHOWCONTAINER&vCONTAINERID=11
In developing countries, sepsis accounts for 60-80% of all deaths. It kills more than 6 million infants and young children, and 100,000 new mothers every year. Every few seconds, someone in the world dies of sepsis.
This is why DARPA will make AEMD a necessity worldwide
http://www.forbes.com/sites/robertpearl/2013/08/08/why-70000-americans-die-needlessly-in-hospitals-each-year/?optimizely=a
Conner misses a key factor
10 billion ? Really ?
Regardless. What Dr Conner has to swallow is that the HP in ONE treatment removed 99.7% of viral load 400k to 1 k with no future increase
So if it was 4,000,000 parts per ML it would have dropped it to 10,000 which would have still been a safe level
A patient ( if he had levels in the billions) could receive a few treatments and still wipe out viral load
From the following report.
Patients with a viral load > 100,000 copies per m/l. Has a 33% chance of dying
Those with viral load > 10,000,000 copies has a 94% chance of death
http://www.uptodate.com/contents/epidemiology-pathogenesis-and-clinical-manifestations-of-ebola-and-marburg-virus-disease
No mention of Billions
As an example if a patient with 20,000,000 copies m/l of viral load was treated it HP at 99.7 % rival rate he would be brought down to 60,000 copies m/l and this increase survival chances by several hundred percent
Conner can't deny that reducing viral load saves lives
99.7 % reduction in viral load in one treatment !
Viral load did not increase after treatment
Now apply this same tech to other diseases
Sepsis
HCV
HIV
CTE
Cancer
Dengue
Avain Bird
Tens of millions of patients yearly
AEMD. Game Changer
THIS.....from today
http://chimpreports.com/dr-mawanda-successfully-cured-of-ebola/
Like I said. Geiger is here with a purpose. Confirming to the world what we know during "kidney week"
Dr Helmut Geiger, the head of nephrology at his hospital , is not flying
To America for a 20 minute presentation to tell the world it didn't work.
He is flying thousands of miles and taking time away from patients because the message he is being asked to deliver holds a great importance and the impact of him being here speaks volumes
http://www.kgu.de/fachkliniken/zentrum-der-inneren-medizin/medizinische-klinik-iii-kardiologie-angiologie-nephrologie/nephrologie.html
Ebola report from Germany on Friday according to slides.
Timeline for expected studies and reporting also listed
Ace. There are several on this board, myself included , who hold high six figure or a million to several million shares.
Your enthusiasm is positive which is better than those looking to push shares down The reality of AEMD moving to dollars in weeks is highly unlikely. $10 a share would be great for you but is world changing for many of us. I guess that's why we temper and endure the pumpers and the rah rah predictions. We expect great things or we would have opened the positions we have but patience is needed
It realistically is years away from multi dollar possibilities unless the unexpected happens. Next week or weeks? No